The abstract is read at the publisher; the summary is JClub's.
AAV6.2FF-encoded concatemeric CaV3.2 inhibitory peptide aptamer (Co3.2iPA) relieves tibial nerve injury–induced pain behaviors for 4 months in rats, with similar effects in males and females.
- Why it matters: Long-lasting, peripherally targeted analgesia is needed for intractable chronic pain, especially when current therapies fail, and translational validation in human sensory neurons is required.
- What they did: Rats with tibial nerve injury received lumbar dorsal root ganglion injections of AAV6.2FF-Co3.2iPA, and pain behaviors were tracked for months; peripheral restriction and expression were checked by immunohistochemistry and AAV genome analysis.
- The result: Co3.2iPA showed peripheral nerve–restricted biodistribution and long-term transgene expression, and in human sensory neurons it inhibited T-type calcium channels and suppressed action potential firing, supporting DRG delivery for chronic pain.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.